Search

Your search keyword '"Etra, Aaron"' showing total 26 results
Start Over Author "Etra, Aaron" Search Limiters Academic (Peer-Reviewed) Journals
26 results on '"Etra, Aaron"'

1. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Author

Akahoshi, Yu, Spyrou, Nikolaos, Weber, Daniela, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Chanswangphuwana, Chantiya, Choe, Hannah K., Eder, Matthias, Etra, Aaron M., Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr M., Merli, Pietro, Qayed, Muna, Reshef, Ran, Schechter, Tal, Ullrich, Evelyn, Vasova, Ingrid, Wölfl, Matthias, Zeiser, Robert, Baez, Janna, Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Katsivelos, Nikolaos, Kowalyk, Steven, Morales, George, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Levine, John E., and Ferrara, James L. M.

Published
2024
Full Text
View/download PDF

2. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

Author

DeFilipp, Zachariah, Kim, Haesook T., Spyrou, Nikolaos, Katsivelos, Nikolaos, Kowalyk, Steven, Eng, Gilbert, Kasikis, Stelios, Beheshti, Rahnuma, Baez, Janna, Akahoshi, Yu, Ayuk, Francis, Choe, Hannah, Etra, Aaron, Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Qayed, Muna, Reshef, Ran, Vasova, Ingrid, Zeiser, Robert, Young, Rachel, Holler, Ernst, Ferrara, James L. M., Nakamura, Ryotaro, Levine, John E., and Chen, Yi-Bin

Published
2024
Full Text
View/download PDF

3. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Author

Etra, Aaron, El Jurdi, Najla, Katsivelos, Nikolaos, Kwon, Deukwoo, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Kowalyk, Steven, Aguayo-Hiraldo, Paibel, Akahoshi, Yu, Ayuk, Francis, Baez, Janna, Betts, Brian C., Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gleich, Sigrun, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr, MacMillan, Margaret, Pawarode, Attaphol, Quagliarella, Francesco, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Weisdorf, Daniel, Wölfl, Matthias, Young, Rachel, Nakamura, Ryotaro, Ferrara, James L. M., Levine, John E., and Holtan, Shernan

Published
2024
Full Text
View/download PDF

4. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Author

Akahoshi, Yu, Spyrou, Nikolaos, Hoepting, Matthias, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Chanswangphuwana, Chantiya, Choe, Hannah K., Eder, Matthias, Etra, Aaron M., Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr M., Merli, Pietro, Qayed, Muna, Reshef, Ran, Schechter, Tal, Ullrich, Evelyn, Vasova, Ingrid, Wölfl, Matthias, Zeiser, Robert, Baez, Janna, Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Kasikis, Stelios, Katsivelos, Nikolaos, Kowalyk, Steven, Morales, George, Young, Rachel, DeFilipp, Zachariah, Ferrara, James L. M., Levine, John E., and Nakamura, Ryotaro

Published
2024
Full Text
View/download PDF

5. A Day 14 Endpoint for Acute GVHD Clinical Trials

Author

Spyrou, Nikolaos, Akahoshi, Yu, Kowalyk, Steven, Morales, George, Beheshti, Rahnuma, Aguayo-Hiraldo, Paibel, Al Malki, Monzr M., Ayuk, Francis, Bader, Peter, Baez, Janna, Capellini, Alexandra, Choe, Hannah, DeFilipp, Zachariah, Eder, Matthias, Eng, Gilbert, Etra, Aaron, Gleich, Sigrun, Grupp, Stephan A., Hexner, Elizabeth, Hoepting, Matthias, Hogan, William J., Kasikis, Stelios, Katsivelos, Nikolaos, Khan, Alina, Kitko, Carrie L., Kraus, Sabrina, Kwon, Deukwoo, Merli, Pietro, Portelli, Joseph, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Holler, Ernst, Chen, Yi-Bin, Nakamura, Ryotaro, Levine, John E., and Ferrara, James L.M.

Published
2024
Full Text
View/download PDF

6. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Author

Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu, Hogan, William J., Etra, Aaron, Choe, Hannah, Hexner, Elizabeth, Langston, Amelia, Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M., and Levine, John E.

Published
2023
Full Text
View/download PDF

7. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Author

Akahoshi, Yu, Spyrou, Nikolaos, Hogan, William J., Ayuk, Francis, DeFilipp, Zachariah, Weber, Daniela, Choe, Hannah K., Hexner, Elizabeth O., Rösler, Wolf, Etra, Aaron M., Sandhu, Karamjeet, Yanik, Gregory A., Chanswangphuwana, Chantiya, Kitko, Carrie L., Reshef, Ran, Kraus, Sabrina, Wölfl, Matthias, Eder, Matthias, Bertrand, Hannah, Qayed, Muna, Merli, Pietro, Grupp, Stephan A., Aguayo-Hiraldo, Paibel, Schechter, Tal, Ullrich, Evelyn, Baez, Janna, Beheshti, Rahnuma, Gleich, Sigrun, Kowalyk, Steven, Morales, George, Young, Rachel, Kwon, Deukwoo, Nakamura, Ryotaro, Levine, John E., Ferrara, James L. M., and Chen, Yi-Bin

Published
2023
Full Text
View/download PDF

8. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Author

Etra, Aaron, Capellini, Alexandra, Alousi, Amin, Al Malki, Monzr M., Choe, Hannah, DeFilipp, Zachariah, Hogan, William J., Kitko, Carrie L., Ayuk, Francis, Baez, Janna, Gandhi, Isha, Kasikis, Stelios, Gleich, Sigrun, Hexner, Elizabeth, Hoepting, Matthias, Kapoor, Urvi, Kowalyk, Steven, Kwon, Deukwoo, Langston, Amelia, Mielcarek, Marco, Morales, George, Özbek, Umut, Qayed, Muna, Reshef, Ran, Rösler, Wolf, Spyrou, Nikolaos, Young, Rachel, Chen, Yi-Bin, Ferrara, James L. M., and Levine, John E.

Published
2023
Full Text
View/download PDF

9. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

Author

Qayed, Muna, Kapoor, Urvi, Gillespie, Scott, Westbrook, Adrianna, Aguayo-Hiraldo, Paibel, Ayuk, Francis A., Aziz, Mina, Baez, Janna, Choe, Hannah, DeFilipp, Zachariah, Etra, Aaron, Grupp, Stephan A., Hexner, Elizabeth, Holler, Ernst, Hogan, William J., Kowalyk, Steven, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Pulsipher, Michael A., Schechter, Tal, Shah, Jay, Spyrou, Nikolaos, Srinagesh, Hrishikesh K., Wölfl, Matthias, Yanik, Gregory, Young, Rachel, Kitko, Carrie L., Ferrara, James L.M., and Levine, John E.

Published
2024
Full Text
View/download PDF

11. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

Author

Etra, Aaron, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Shah, Jay, Kowalyk, Steven, Ayuk, Francis, Baez, Janna, Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gandhi, Isha, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kapoor, Urvi, Kitko, Carrie L., Kraus, Sabrina, Lin, Jung-Yi, Al Malki, Monzr, Merli, Pietro, Pawarode, Attaphol, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Van Hyfte, Grace, Weber, Daniela, Wölfl, Matthias, Young, Rachel, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2022
Full Text
View/download PDF

12. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Author

Gergoudis, Stephanie C., DeFilipp, Zachariah, Özbek, Umut, Sandhu, Karamjeet S., Etra, Aaron M., Choe, Hannah K., Kitko, Carrie L., Ayuk, Francis, Aziz, Mina, Baez, Janna, Ben-David, Kaitlyn, Bunworasate, Udomsak, Gandhi, Isha, Hexner, Elizabeth O., Hogan, William J., Holler, Ernst, Kasikis, Stelios, Kowalyk, Steven M., Lin, Jung-Yi, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Reshef, Ran, Rösler, Wolf, Srinagesh, Hrishikesh, Young, Rachel, Chen, Yi-Bin, Ferrara, James L.M., and Levine, John E.

Published
2020
Full Text
View/download PDF

13. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

Author

Srinagesh, Hrishikesh K., Özbek, Umut, Kapoor, Urvi, Ayuk, Francis, Aziz, Mina, Ben-David, Kaitlyn, Choe, Hannah K., DeFilipp, Zachariah, Etra, Aaron, Grupp, Stephan A., Hartwell, Matthew J., Hexner, Elizabeth O., Hogan, William J., Karol, Alexander B., Kasikis, Stelios, Kitko, Carrie L., Kowalyk, Steven, Lin, Jung-Yi, Major-Monfried, Hannah, Mielke, Stephan, Merli, Pietro, Morales, George, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reddy, Pavan, Reshef, Ran, Rösler, Wolf, Sandhu, Karamjeet S., Schechter, Tal, Shah, Jay, Sigel, Keith, Weber, Daniela, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Levine, John E., and Ferrara, James L.M.

Published
2019
Full Text
View/download PDF

14. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

Author

Aziz, Mina D., Shah, Jay, Kapoor, Urvi, Dimopoulos, Christina, Anand, Sarah, Augustine, Allan, Ayuk, Francis, Chaudhry, Mohammed, Chen, Yi-Bin, Choe, Hannah K., Etra, Aaron, Gergoudis, Stephanie, Hartwell, Matthew J., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kowalyk, Steven, Kröger, Nicolaus, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Schreiner, Elisabeth, Srinagesh, Hrishikesh, Wölfl, Matthias, Wudhikarn, Kitsada, Yanik, Gregory, Young, Rachel, Özbek, Umut, Ferrara, James L. M., and Levine, John E.

Published
2020
Full Text
View/download PDF

15. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Author

Major-Monfried, Hannah, Renteria, Anne S., Pawarode, Attaphol, Reddy, Pavan, Ayuk, Francis, Holler, Ernst, Efebera, Yvonne A., Hogan, William J., Wölfl, Matthias, Qayed, Muna, Hexner, Elizabeth O., Wudhikarn, Kitsada, Ordemann, Rainer, Young, Rachel, Shah, Jay, Hartwell, Matthew J., Chaudhry, Mohammed S., Aziz, Mina, Etra, Aaron, Yanik, Gregory A., Kröger, Nicolaus, Weber, Daniela, Chen, Yi-Bin, Nakamura, Ryotaro, Rösler, Wolf, Kitko, Carrie L., Harris, Andrew C., Pulsipher, Michael, Reshef, Ran, Kowalyk, Steven, Morales, George, Torres, Ivan, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2018
Full Text
View/download PDF

16. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease

Author

Zewde, Makda Getachew, Morales, George, Gandhi, Isha, Özbek, Umut, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Baez, Janna, Chanswangphuwana, Chantiya, Choe, Hannah, DeFilipp, Zachariah, Etra, Aaron, Grupp, Stephan, Hexner, Elizabeth O., Hogan, William, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kitko, Carrie L., Kowalyk, Steven, Meedt, Elisabeth, Merli, Pietro, Nakamura, Ryotaro, Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Weber, Daniela, Wölfl, Matthias, Yanik, Gregory, Young, Rachel, Levine, John E., Ferrara, James L.M., and Chen, Yi-Bin

Published
2021
Full Text
View/download PDF

17. Death of Woman with peripartum influenza B virus infection and necrotizing pneumonia

Author

Rein, Joshua L., Etra, Aaron M., Patel, Jatinbhai J., Stein, Janet L., Rivers, Aimee L., Gershengorn, Hayley B., Awerbuch, Elizabeth, Kreiswirth, Barry N., and Koshy, Sanjana C.

Subjects
Influenza -- Case studies -- Diagnosis -- Care and treatment, Staphylococcus aureus infections -- Case studies -- Diagnosis -- Care and treatment, Pregnancy, Complications of -- Case studies -- Diagnosis -- Care and treatment, Health
Abstract

To the Editor: Pregnant women are at increased risk for severe influenza-related complications (1). Bacterial pneumonia with Panton-Valentine leukocidin-producing (PVL) Staphylococcus aureus is infrequently described in the literature as occurring [...]

Published
2014
Full Text
View/download PDF

18. Bulletin

Author

Schwind, Michael A., Carey, John, and Etra, Aaron

Published
1965

19. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.

Author

Kasikis, Stelios, Etra, Aaron, and Levine, John E.

Subjects
*GRAFT versus host disease, *ACUTE diseases, *PROTEIN-tyrosine kinases, *PROTEASOME inhibitors, *T cells
Abstract

Acute graft-versus-host disease (GVHD), the major complication after allogeneic hematopoietic cell transplant (HCT), develops in approximately 50% of patients. The primary treatment is high-dose systemic steroids, but treatment failure is common, and steroid-refractory (SR) GVHD is the leading cause of non-relapse mortality after allogeneic HCT. Ruxolitinib became the first treatment for SR GVHD to obtain US Food and Drug Administration approval, and other new treatments are actively being studied. We searched the literature using the PubMed database and clinical trials using ClinicalTrials.gov to identify the most promising new treatments for GVHD. In this review, we categorize potential new treatments for GVHD by their mechanism of action (e.g., antibodies that deplete T cells or prevent their trafficking to target tissues, proteasome inhibitors, tyrosine kinase inhibitors, and other agents) and summarize the results from clinical trials. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

23. Insights from the Front Lines of Nutraceutical Research: The Third International Conference on Mechanisms of Action of Nutraceuticals (ICMAN 3).

Author

Pavelic, Kresimir, Etra, Aaron, and Gall-Troselj, Koraljka

Subjects
*CONFERENCES & conventions, *FUNCTIONAL foods, *NEURODEGENERATION, *CANCER, *TECHNOLOGY, *DIABETES
Abstract

The article presents information on the Third International Conference on Mechanisms of Action of Nutraceuticals. The topics considered at the conference were regulation of nutraceuticals, nutraceuticals for neuroprotection and neurodegenerative diseases, nutraceuticals and cancer, nutraceuticals and cardiovascular diseases, nutraceuticals and diabetes, and the role of new technologies. Major advances have been made in recent years in understanding the molecular and cellular basis of nutraceutical action. Nutraceutical research is moving away from the tracing of individual events to a more integrated approach looking at the interplay and coordination between many events. The clear and important role of omics methodologies was evident during the entire meeting.

Published
2005
Full Text
View/download PDF

24. Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality.

Author

Etra, Aaron, Gergoudis, Stephanie, Morales, George, Kowalyk, Steven, Lin, Jung-Yi, Shah, Jay, Kapoor, Urvi, Aziz, Mina, Pawarode, Attaphol, Ayuk, Francis, Holler, Ernst, Choe, Hannah, Chen, Yi-Bin, Rösler, Wolf, Qayed, Muna, Hogan, William J., Wolfl, Matthias, Hexner, Elizabeth O., Merli, Pietro, and Kitko, Carrie L.

Subjects
*GRAFT versus host disease, *BLOOD serum analysis, *COMPUTER algorithms, *RECEIVER operating characteristic curves, *ACCURACY
Abstract

Acute GVHD biomarkers predict long-term outcomes after GVHD diagnosis. Our group has validated the MAGIC algorithm which uses the concentrations of 2 GVHD biomarkers, ST2+REG3a, to predict lethal GVHD (defined as death from GVHD without relapse) [Hartwell 2017]. Other published biomarker combinations that predict GVHD outcomes include ST2+ REG3a+TNFR1 [Levine 2015], ST2+TIM3 [Abu Zaid 2017], ST2+TNFR1 [McDonald 2015], TIM3+TNFR1+IL6 [McDonald 2015], as well as AREG alone [Holtan 2018]. It is not clear which biomarker combination best predicts lethal GVHD because these algorithms were developed using different patient cohorts with different endpoints. To answer this question, we compared the predictive accuracy of different biomarker combinations as well as these six specific combinations in the same patient cohort. We studied 522 patients with serum samples at GVHD diagnosis who were transplanted at 19 Mount Sinai Acute GVHD International Consortium (MAGIC) centers between January 1, 2004 and April 30, 2017. Patients were divided into training (n = 253) and validation (n = 269) sets; validation patients were transplanted after November 1, 2015 and had not previously been used to generate an algorithm. Biomarkers were measured by ELISA and log-transformed values were used to predict 1-year lethal GVHD by competing risk regression. Four of the 6 biomarkers (ST2, REG3a, TNFR1, and TIM3) independently predicted lethal GVHD in the training set. We then developed algorithms that predicted lethal GVHD using all possible combinations of these 4 biomarkers as well as the published combination of TIM3+TNFR1+IL6 and AREG alone. The best algorithms of 1-4 biomarkers for predicting lethal GVHD were REG3a alone, ST2+REG3a, ST2+REG3a+TNFR1, and ST2+REG3a+TNFR1+TIM3. While ST2+REG3a was the most accurate combination based on the lowest Akaike Information Criterion (AIC), the other published biomarker combinations produced similar AICs. Therefore, we used the independent validation set to compare all six published algorithms. We generated area under the receiver operating characteristic curves (AUC) for each algorithm (FIG 1). We next determined the threshold that maximized sensitivity and specificity for each algorithm and calculated the cumulative incidence of lethal GVHD in the resulting high and low risk strata (FIG 2). Highly similar results were obtained when the cumulative incidence of non-relapse mortality was used as the endpoint. In a validation set of previously unanalyzed patients, several biomarker combinations reproducibly stratified patients with GVHD for risk of death. The best 4 algorithms, all of which included ST2, produced comparable outcomes. Adding TNFR1 to ST2+ REG3a did not improve accuracy. The ST2+REG3a algorithm best identifies patients at onset of GVHD for high risk of lethal GVHD and NRM, and thus remains a standard for biomarker-based risk prediction. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

26. The MAGIC Algorithm Probability (MAP) Is a Validated Response Biomarker of Treatment for Acute Graft-Versus-Host Disease.

Author

Srinagesh, Hrishikesh K., Ozbek, Umut, Kapoor, Urvi, Ayuk, Francis, Aziz, Mina, Ben-David, Kaitlyn, Choe, Hannah, DeFilipp, Zack, Etra, Aaron, Grupp, Stephan A., Hartwell, Matthew J., Hexner, Elizabeth, Hogan, William J., Karol, Alexander B., Kasikis, Stelios, Kitko, Carrie Lynn, Kowalyk, Steven, Major-Monfried, Hannah, Lin, Jung-Yi, and Mielke, Stephan

Subjects
*GRAFT versus host disease, *RECEIVER operating characteristic curves, *ACUTE diseases
Abstract

There are no validated biomarkers that measure a patient's response to therapy for acute graft-versus-host disease (GVHD), the leading cause of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplant (HCT). Recent studies from the Mount Sinai Acute GVHD International Consortium (MAGIC) have validated an algorithm probability (MAP) that combines serum concentrations of two biomarkers of GVHD (REG3α and ST2) to generate an estimated probability of 6 month NRM for individual patients. The MAP estimates GVHD-mediated damage to crypts throughout the lower GI tract at single time points (Hartwell et al., JCI Insight , 2017; Major- Monfried et al., Blood , 2018). We hypothesized that the change in MAP between start of treatment and 28 days later could serve as a response biomarker and would compare favorably to clinical response, the gold standard which is widely used as a surrogate for long term survival and is the primary endpoint in most GVHD treatment trials (Martin et al., BBMT , 2009; MacMillan et al., Blood , 2010). We prospectively collected serum samples and clinical staging from 368 sequential HCT patients who received systemic treatment for acute GVHD in one of 20 MAGIC centers between January 2016 and February 2018. We computed MAPs and clinical responses for each patient. MAPs of patients who experienced 6 month NRM increased significantly compared to MAPs of patients who survived (p=0.0004). In patients whose initial MAPs were low (Ann Arbor 1, MAP < 0.141) or intermediate (Ann Arbor 2, 0.141 ≤ MAP ≤ 0.290), 6 month NRM clustered among those with the greatest increases in MAP after 28 days (Fig 1A,B). In patients with high initial MAPs (Ann Arbor 3, MAP > 0.290), those who survived tended to have the largest decreases in MAP (Fig 1C). We found that patients whose MAPs rose above the previously determined high-risk threshold MAP of 0.290 had significantly worse survival compared to those who remained below it, whereas the large number patients with initially high MAPs that remained above the threshold had a large increase in mortality (Fig 2). When measured at day 28, MAPs predicted NRM more accurately than clinical responses, with areas under the receiver operating characteristic curve (AUC) of 0.86 and 0.70, respectively (p<0.0001). An algorithm that combined clinical response with biomarkers generated the same AUC as the MAP alone (0.83 v 0.86, p = NS). The same MAP threshold predicted risk of NRM within both clinical responders and non-responders after four weeks of treatment (Fig 3), and in those with and without significant lower GI symptoms (Fig 4). We conclude that the MAP is, to our knowledge, the first laboratory test validated as a response biomarker for acute GVHD treatment and more accurately predicts survival than clinical response after 28 days of treatment. The MAP may serve as a novel endpoint in future trials of GVHD treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results